Invivo Therapeutics Holdings Corp (NVIV) versus Its Competitors Head-To-Head Contrast
Invivo Therapeutics Holdings Corp (OTCMKTS: NVIV) is one of 87 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it weigh in compared to its rivals? We will compare Invivo Therapeutics Holdings Corp to similar businesses based on the strength of its earnings, dividends, analyst recommendations, institutional ownership, risk, profitability and valuation.
Risk & Volatility
Invivo Therapeutics Holdings Corp has a beta of 3.27, meaning that its share price is 227% more volatile than the S&P 500. Comparatively, Invivo Therapeutics Holdings Corp’s rivals have a beta of 1.24, meaning that their average share price is 24% more volatile than the S&P 500.
Insider & Institutional Ownership
51.1% of shares of all “Advanced Medical Equipment & Technology” companies are held by institutional investors. 18.7% of shares of all “Advanced Medical Equipment & Technology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares Invivo Therapeutics Holdings Corp and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Invivo Therapeutics Holdings Corp||N/A||N/A||-1.59|
|Invivo Therapeutics Holdings Corp Competitors||$2.13 billion||$221.25 million||2.04|
Invivo Therapeutics Holdings Corp’s rivals have higher revenue and earnings than Invivo Therapeutics Holdings Corp. Invivo Therapeutics Holdings Corp is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This table compares Invivo Therapeutics Holdings Corp and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Invivo Therapeutics Holdings Corp||N/A||-118.45%||-96.82%|
|Invivo Therapeutics Holdings Corp Competitors||-299.57%||-36.17%||-12.71%|
This is a breakdown of recent ratings and recommmendations for Invivo Therapeutics Holdings Corp and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Invivo Therapeutics Holdings Corp||0||1||0||0||2.00|
|Invivo Therapeutics Holdings Corp Competitors||267||1867||3359||108||2.59|
Invivo Therapeutics Holdings Corp presently has a consensus target price of $6.00, indicating a potential upside of 344.44%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 11.82%. Given Invivo Therapeutics Holdings Corp’s higher possible upside, equities research analysts plainly believe Invivo Therapeutics Holdings Corp is more favorable than its rivals.
Invivo Therapeutics Holdings Corp rivals beat Invivo Therapeutics Holdings Corp on 8 of the 11 factors compared.
Invivo Therapeutics Holdings Corp Company Profile
InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company’s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers, which include poly lactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL). The Company is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.
Receive News & Ratings for Invivo Therapeutics Holdings Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivo Therapeutics Holdings Corp and related companies with MarketBeat.com's FREE daily email newsletter.